Some studies have suggested that the scavenger receptor CD163 is upregulated in the presence of pathologies characterised by chronic inflammation such as atherosclerosis and T2D allowing it to neutralise the biological activity of sTWEAK [79, 80]. Here, CD163 is linked to atherosclerosis.